Results 61 to 70 of about 30,003 (256)
Prophylactic approaches to graft versus host disease (GvHD) have employed both phenotypic reduction of T cells and selective elimination of host-primed donor T cells in vitro and in vivo.
Shai eYarkoni +3 more
doaj +1 more source
Engineered mesoporous silica nanoparticles (Silicasomes) enable systemic delivery of the STING agonist ADU‐S100, overcoming the instability and toxicity that limit cyclic dinucleotides to local administration. By enhancing tumor accumulation, activating systemic antitumor immunity, and remodeling the tumor immune microenvironment, these nanoparticles ...
Wenjing Zhou +10 more
wiley +1 more source
Multiplex Genotyping of Human Minor Histocompatibility Antigens
Minor histocompatibility antigens (mHAg) induce major histocompatibility complex-restricted, T cell-mediated immune responses that may contribute to increased risk of graft-versus-host disease and graft-versus-leukemia effects. Unlike human leukocyte antigen genes, mHAg are encoded by genetically and functionally unrelated genes located throughout the ...
Pietz, B.C. +3 more
openaire +2 more sources
This study elucidates the mechanisms of subcellular multidimensional collapse in exhausted T cells. By specifically targeting the nucleus, mitochondria, and endoplasmic reticulum, strategic interventions can effectively remodel the compromised organelle network. This integrated approach drives comprehensive T cell resuscitation, ultimately establishing
Mingxing Wang +9 more
wiley +1 more source
Genetic mismatches in protein coding genes between allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipient and donor can elicit an alloimmunity response via peptides presented by the recipient HLA receptors as minor histocompatibility ...
Jarmo Ritari +12 more
doaj +1 more source
The Role of Direct Presentation by Donor Dendritic Cells in Rejection of Minor Histocompatibility Antigen-Mismatched Skin and Hematopoietic Cell Grafts [PDF]
Background. The success of transplantation is hampered by rejection of the graft by alloreactive T cells. Donor dendritic cells (DC) have been shown to be required for direct priming of immune responses to antigens from major histocompatibility complex ...
Bennett, C.L. +17 more
core +1 more source
Optimization of the HA-1-specific T-cell receptor for gene therapy of hematologic malignancies
To broaden the applicability of adoptive T-cell therapy for the treatment of hematologic malignancies, we aim to start a clinical trial using HA-1-TCR transferred virus-specific T cells.
Marleen M. van Loenen +5 more
doaj +1 more source
Use of monoclonal antibodies to study alloreactivity and T cell development in Xenopus [PDF]
This study investigated T-cell surface antigenic changes in the spleen of Xenopus following in vivo and in vitro allergenic challenge, using novel mouse monoclonal antibodies (mAb's) against all T cells (CDS), the putative ɑβ-T cell receptor (TCR), the ...
Paul, Tina
core
Binding of HSV-1 glycoprotein K (gK) to signal peptide peptidase (SPP) is required for virus infectivity. [PDF]
Glycoprotein K (gK) is a virion envelope protein of herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), which plays important roles in virion entry, morphogenesis and egress.
Sariah J Allen +5 more
doaj +1 more source
Efficacy, safety and cost‐effectiveness of CAR‐T therapy
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher +7 more
wiley +1 more source

